logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Merida Therapeutics has launched with a $121 million Series A funding round co-led by Third Rock Ventures and Bain Capital Life Sciences. This funding will support the company's development of Fc-based therapeutics for autoimmune disorders.

Apr 08, 2025•8 months ago

Amount Raised

$121 Million

Round Type

series a

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

Perceptive Xontogeny Venture FundsGvBvf PartnersBain Capital Life SciencesThird Rock Ventures

Description

Merida Therapeutics has officially unveiled its drug development platform and secured $121 million in Series A financing. Third Rock Ventures co-led the round alongside Bain Capital Life Sciences and other notable investors. The funds will be used to advance their protein engineering platform aimed at treating autoimmune diseases like Graves' disease. The lead program is focused on precision therapeutics targeting pathogenic antibodies.

Company Information

Company

Merida Therapeutics

Location

Cambridge, Massachusetts, United States

About

Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech